Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Groundbreaking gene therapy aims to fix immune system in rare disease

NCT ID NCT06559176

First seen Apr 14, 2026 · Last updated May 24, 2026 · Updated 7 times

Summary

This study tests a new gene therapy called PM359 for people with a rare immune disorder called chronic granulomatous disease (CGD). The therapy takes the patient's own blood stem cells, fixes a specific gene mutation using a precise editing tool called prime editing, and then returns the corrected cells to the patient. The goal is to restore the immune system's ability to fight infections. The study involves 12 participants and will monitor safety and effectiveness over 15 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRANULOMATOUS DISEASE, CHRONIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU - Sainte Justine Hospital

    Montreal, Quebec, H3T 1C5, Canada

  • NIH Clinical Center

    Bethesda, Maryland, 20892, United States

  • The Children's Hospital at Tristar Medical Group/Sarah Cannon Center for Blood Cancers

    Nashville, Tennessee, 37203, United States

  • University College of London Hospital

    London, England, NW1 2PG, United Kingdom

  • University of California Los Angeles Medical Center

    Los Angeles, California, 90027, United States

Conditions

Explore the condition pages connected to this study.